Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids
Dirkje S Postma, Richard Dekhuijzen, Thys van der Molen, Richard J Martin, Wim van Aalderen, Nicolas Roche, Theresa W Guilbert, Elliot Israel, Daniela van Eickels, Javaria Mona Khalid, Ron MC Herings, Jetty A Overbeek, Cristiana Miglio, Victoria Thomas, Catherine Hutton, Elizabeth V Hillyer, David B Price
Allergy, Asthma & Immunology Research | KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY | Published : 2017
Funds to acquire the dataset from the PHARMO Institute were provided by Research in Real-Life, Ltd (RiRL). The study data were provided to the Small Airways Study Group (SASG), which received financial support to conduct the analyses from Takeda Pharmaceuticals International GmbH, Zurich, Switzerland. Two Takeda employees (D.vE. and J.M.K.) are authors of the paper and participated in developing the study protocol and the manuscript. Members of the SASG were reimbursed for travel expenses to attend meetings to discuss this together with several other projects; they were not otherwise compensated for their advisory role.